CytoMed Therapeutics Limited (GDTC) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 130.63K | 105.7K | 100.04K | 52.41K | 108.62K | 82.67K | 83.11K | 84.69K | 81.75K | 105.08K | 106.78K | 108.02K |
| Revenue Growth % | 149.21% | 27.87% | 20.38% | -38.11% | 32.87% | -21.33% | -22.17% | -21.6% | -18.85% | - | 288.31% | - |
| Cost of Goods Sold | 562.8K | 7.33K | 6.93K | 10.56K | 11.22K | 123.87K | 819 | 898 | 867 | 151.97K | 2.29K | 39.09K |
| COGS % of Revenue | 430.85% | 6.93% | 6.93% | 20.14% | 10.33% | 149.85% | 0.98% | 1.06% | 1.06% | 144.62% | 2.15% | 36.19% |
| Gross Profit | -432.18K | 98.38K | 93.11K | 91.66K | 97.4K | 81.85K | 82.29K | 83.79K | 80.88K | -46.89K | 104.49K | 68.93K |
| Gross Margin % | -330.85% | 93.07% | 93.07% | 174.86% | 89.67% | 99.02% | 99.01% | 98.94% | 98.94% | -44.62% | 97.85% | 63.81% |
| Gross Profit Growth % | -571.52% | 20.19% | 13.15% | 9.39% | 20.42% | 274.57% | -21.25% | 21.56% | -18.3% | -11.71% | 299.99% | 270.65% |
| Operating Expenses | 1.4M | 608.93K | 576.31K | 466.02K | 495.22K | 1.27M | 475.59K | 414.8K | 400.41K | 363.83K | 369.72K | 385.67K |
| OpEx % of Revenue | 1072.21% | 576.07% | 576.07% | 889.1% | 455.93% | 1535.95% | 572.27% | 489.81% | 489.81% | 346.23% | 346.23% | 357.03% |
| Selling, General & Admin | 579.18K | 151.82K | 143.69K | 123.67K | 131.42K | 113.77K | 114.38K | 119.88K | 115.72K | 514.86K | 64.9K | 42.71K |
| SG&A % of Revenue | 443.39% | 143.63% | 143.63% | 235.94% | 120.99% | 137.62% | 137.63% | 141.56% | 141.56% | 489.95% | 60.78% | 39.54% |
| Research & Development | 817.89K | 457.11K | 432.63K | 342.36K | 363.81K | 633.72K | 361.22K | 294.91K | 284.68K | 299.96K | 304.82K | 342.96K |
| R&D % of Revenue | 626.13% | 432.44% | 432.44% | 653.16% | 334.94% | 766.59% | 434.65% | 348.25% | 348.25% | 285.45% | 285.45% | 317.49% |
| Other Operating Expenses | 3.51K | 0 | 0 | 0 | 0 | 522.23K | 0 | 0 | 0 | -451K | 0 | 0 |
| Operating Income | -1.83M | -510.55K | -483.2K | -1.23M | -397.82K | -1.39M | -393.3K | -331.01K | -663.19K | -1.16M | -762.52K | -1.03M |
| Operating Margin % | -1403.06% | -483% | -483% | -2348.64% | -366.26% | -1685.8% | -473.26% | -390.87% | -811.28% | -1107.5% | -714.07% | -950.17% |
| Operating Income Growth % | -48.88% | 63.36% | -22.86% | -271.91% | 40.01% | -19.74% | 48.42% | 67.75% | -154.42% | -74.5% | -227.21% | -29.74% |
| EBITDA | -1.73M | -439.98K | -416.42K | -1.17M | -334.47K | -1.27M | -331.44K | -292.78K | -598.87K | -1.01M | -686.22K | -987.29K |
| EBITDA Margin % | -1324.64% | -416.24% | -416.24% | -2234.9% | -307.94% | -1535.96% | -398.82% | -345.73% | -732.59% | -962.88% | -642.62% | -913.98% |
| EBITDA Growth % | -47.71% | 65.35% | -25.64% | -300.11% | 44.15% | -25.49% | 51.7% | 70.35% | -213.12% | -61.9% | -322.08% | -31.51% |
| D&A (Non-Cash Add-back) | 102.44K | 70.57K | 66.79K | 59.62K | 63.35K | 123.87K | 61.86K | 38.23K | 64.32K | 151.97K | 76.3K | 39.09K |
| EBIT | -1.83M | -874.89K | -828.03K | -542.06K | -576.02K | -812.62K | -611.64K | -1.45M | -663.19K | -1.57M | -762.52K | -1.48M |
| Net Interest Income | 21.32K | 57.02K | -3.84K | 87.95K | 45.37K | 134.17K | 67K | 179.66K | 88.7K | -6.05K | -3.04K | -44.88K |
| Interest Income | 29.54K | 64.81K | 0 | 95.88K | 45.37K | 141.44K | 67K | 187.46K | 88.7K | 24.45K | 3.04K | 452 |
| Interest Expense | 8.21K | 7.79K | 3.84K | 7.92K | 0 | 7.28K | 0 | 7.8K | 0 | 30.5K | 0 | 45.33K |
| Other Income/Expense | 475.71K | -372.56K | -352.61K | 150.09K | -159.8K | 585.53K | -10.23K | 0 | -58.88K | -436.45K | -48.35K | -506.3K |
| Pretax Income | -1.36M | -883.11K | -835.81K | -1.08M | -557.63K | -808.07K | -403.53K | -1.46M | -722.08K | -1.6M | -810.87K | -1.53M |
| Pretax Margin % | -1038.88% | -835.45% | -835.45% | -2059.17% | -513.39% | -977.5% | -485.56% | -1727.01% | -883.3% | -1522.84% | -759.35% | -1418.87% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14.38K | 239 | 0 | -53 | 1.18K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.98% | -0.03% | 0% | 0.01% | -0.08% |
| Net Income | -1.35M | -882.3K | -835.04K | -1.08M | -555.68K | -807.96K | -403.48K | -748.22K | -722.26K | -1.61M | -810.82K | -1.53M |
| Net Margin % | -1030.69% | -834.68% | -834.68% | -2055.08% | -511.59% | -977.37% | -485.5% | -883.53% | -883.54% | -1536.81% | -759.3% | -1419.86% |
| Net Income Growth % | -24.99% | -9.2% | -106.96% | -43.96% | 23.06% | 49.97% | 50.24% | 51.22% | 2.87% | -121.51% | -120.82% | -102.46% |
| Net Income (Continuing) | -1.36M | -883.11K | -835.81K | -1.08M | -557.63K | -808.07K | -403.53K | -748.27K | -722.26K | -1.6M | -810.82K | -1.53M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 309.22K | 59.52K | 56.33K | 56.93K | 60.5K | -811 | -816 | -724 | -699 | -607 | -617 | -509 |
| EPS (Diluted) | -0.11 | -0.07 | -0.07 | -0.09 | -0.05 | -0.07 | -0.04 | -0.06 | -0.06 | -0.14 | -0.08 | -0.14 |
| EPS Growth % | -17.9% | -6.71% | -102% | -43.98% | 23% | 50% | 58.03% | 53.71% | 31.36% | -52.01% | -74.11% | - |
| EPS (Basic) | -0.11 | -0.07 | -0.07 | -0.09 | -0.05 | -0.07 | -0.04 | -0.06 | -0.06 | -0.14 | -0.08 | -0.14 |
| Diluted Shares Outstanding | 11.79M | 11.81M | 11.81M | 11.54M | 11.54M | 11.54M | 11.54M | 11.54M | 11.54M | 11.53M | 9.72M | 10.94M |
| Basic Shares Outstanding | 11.79M | 11.81M | 11.81M | 11.54M | 11.54M | 11.54M | 11.54M | 11.54M | 11.54M | 11.53M | 9.72M | 10.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |